Company intelligence / Profile preview
AltPep Corporation
Seattle, Washington, United Statesaltpep.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Preclinical
01
Overview
AltPep is developing disease-modifying treatments and detection tools for amyloid diseases by targeting early molecular triggers. Their approach focuses on α-sheet, a novel protein structure that is a defining feature of toxic soluble oligomers associated with amyloid diseases.
- Therapeutic areas
- EndocrinologyRare DiseasesNeurology
- Modalities
- Synthetic peptides
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on AltPep Corporation.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AltPep Corporation.